Krystal Biotech, Inc.
NASDAQ:KRYS
Overview | Financials
Company Name | Krystal Biotech, Inc. |
Symbol | KRYS |
Currency | USD |
Price | 156.5 |
Market Cap | 4,501,018,250 |
Dividend Yield | 0% |
52-week-range | 107.5 - 219.34 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Krish S. Krishnan M.B.A., M.S. |
Website | https://www.krystalbio.com |
An error occurred while fetching data.
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD